Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Defining 'T cell exhaustion'.

Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, Schietinger A, Schumacher TN, Schwartzberg PL, Sharpe AH, Speiser DE, Wherry EJ, Youngblood BA, Zehn D.

Nat Rev Immunol. 2019 Sep 30. doi: 10.1038/s41577-019-0221-9. [Epub ahead of print] Review.

PMID:
31570879
2.

TOX is a critical regulator of tumour-specific T cell differentiation.

Scott AC, Dündar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, Trivedi P, Menocal L, Appleby H, Camara S, Zamarin D, Walther T, Snyder A, Femia MR, Comen EA, Wen HY, Hellmann MD, Anandasabapathy N, Liu Y, Altorki NK, Lauer P, Levy O, Glickman MS, Kaye J, Betel D, Philip M, Schietinger A.

Nature. 2019 Jul;571(7764):270-274. doi: 10.1038/s41586-019-1324-y. Epub 2019 Jun 17.

PMID:
31207604
3.

Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections.

Philip M, Schietinger A.

Curr Opin Immunol. 2019 Jun;58:98-103. doi: 10.1016/j.coi.2019.04.014. Epub 2019 Jun 8. Review.

PMID:
31181510
4.

Rejection of immunogenic tumor clones is limited by clonal fraction.

Gejman RS, Chang AY, Jones HF, DiKun K, Hakimi AA, Schietinger A, Scheinberg DA.

Elife. 2018 Nov 30;7. pii: e41090. doi: 10.7554/eLife.41090.

5.

Chromatin states define tumour-specific T cell dysfunction and reprogramming.

Philip M, Fairchild L, Sun L, Horste EL, Camara S, Shakiba M, Scott AC, Viale A, Lauer P, Merghoub T, Hellmann MD, Wolchok JD, Leslie CS, Schietinger A.

Nature. 2017 May 25;545(7655):452-456. doi: 10.1038/nature22367. Epub 2017 May 17.

6.

Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.

Ghosh A, Smith M, James SE, Davila ML, Velardi E, Argyropoulos KV, Gunset G, Perna F, Kreines FM, Levy ER, Lieberman S, Jay HV, Tuckett AZ, Zakrzewski JL, Tan L, Young LF, Takvorian K, Dudakov JA, Jenq RR, Hanash AM, Motta AC, Murphy GF, Liu C, Schietinger A, Sadelain M, van den Brink MR.

Nat Med. 2017 Feb;23(2):242-249. doi: 10.1038/nm.4258. Epub 2017 Jan 9.

7.

Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.

Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, Schell TD, Garbi N, Greenberg PD.

Immunity. 2016 Aug 16;45(2):389-401. doi: 10.1016/j.immuni.2016.07.011. Epub 2016 Aug 9.

8.

Beyond Genomics: Multidimensional Analysis of Cancer Therapy Resistance.

Philip M, Schietinger A.

Trends Immunol. 2015 Nov;36(11):665-667. doi: 10.1016/j.it.2015.09.003. Epub 2015 Oct 1.

9.

Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer.

Schietinger A, Arina A, Liu RB, Wells S, Huang J, Engels B, Bindokas V, Bartkowiak T, Lee D, Herrmann A, Piston DW, Pittet MJ, Lin PC, Zal T, Schreiber H.

Oncoimmunology. 2013 Nov 1;2(11):e26677. Epub 2013 Nov 4.

10.

Tolerance and exhaustion: defining mechanisms of T cell dysfunction.

Schietinger A, Greenberg PD.

Trends Immunol. 2014 Feb;35(2):51-60. doi: 10.1016/j.it.2013.10.001. Epub 2013 Nov 6. Review.

11.

IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner.

Liu RB, Engels B, Schreiber K, Ciszewski C, Schietinger A, Schreiber H, Jabri B.

Proc Natl Acad Sci U S A. 2013 May 14;110(20):8158-63. doi: 10.1073/pnas.1301022110. Epub 2013 May 1.

12.

A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs).

Stone JD, Aggen DH, Schietinger A, Schreiber H, Kranz DM.

Oncoimmunology. 2012 Sep 1;1(6):863-873.

13.

Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer.

Chou CK, Schietinger A, Liggitt HD, Tan X, Funk S, Freeman GJ, Ratliff TL, Greenberg NM, Greenberg PD.

J Immunol. 2012 Oct 15;189(8):3936-46. doi: 10.4049/jimmunol.1201415. Epub 2012 Sep 14.

14.

Densely granulated murine NK cells eradicate large solid tumors.

Liu RB, Engels B, Arina A, Schreiber K, Hyjek E, Schietinger A, Binder DC, Butz E, Krausz T, Rowley DA, Jabri B, Schreiber H.

Cancer Res. 2012 Apr 15;72(8):1964-74. doi: 10.1158/0008-5472.CAN-11-3208. Epub 2012 Feb 28.

15.

Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state.

Schietinger A, Delrow JJ, Basom RS, Blattman JN, Greenberg PD.

Science. 2012 Feb 10;335(6069):723-7. doi: 10.1126/science.1214277. Epub 2012 Jan 19.

16.

Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.

Schietinger A, Philip M, Liu RB, Schreiber K, Schreiber H.

J Exp Med. 2010 Oct 25;207(11):2469-77. doi: 10.1084/jem.20092450. Epub 2010 Oct 4.

17.

Antibody recognition of a unique tumor-specific glycopeptide antigen.

Brooks CL, Schietinger A, Borisova SN, Kufer P, Okon M, Hirama T, Mackenzie CR, Wang LX, Schreiber H, Evans SV.

Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10056-61. doi: 10.1073/pnas.0915176107. Epub 2010 May 17.

18.

Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells.

Philip M, Schietinger A, Schreiber H.

Immunology. 2010 Aug;130(4):494-503. doi: 10.1111/j.1365-2567.2010.03258.x. Epub 2010 Mar 16.

19.

Specificity in cancer immunotherapy.

Schietinger A, Philip M, Schreiber H.

Semin Immunol. 2008 Oct;20(5):276-85. doi: 10.1016/j.smim.2008.07.001. Epub 2008 Aug 5. Review.

20.

Single-particle tunneling in strongly driven double-well potentials.

Kierig E, Schnorrberger U, Schietinger A, Tomkovic J, Oberthaler MK.

Phys Rev Lett. 2008 May 16;100(19):190405. Epub 2008 May 14.

PMID:
18518430
21.

Equilibrium between host and cancer caused by effector T cells killing tumor stroma.

Zhang B, Zhang Y, Bowerman NA, Schietinger A, Fu YX, Kranz DM, Rowley DA, Schreiber H.

Cancer Res. 2008 Mar 1;68(5):1563-71. doi: 10.1158/0008-5472.CAN-07-5324.

22.

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.

Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, Yu P, Fu YX, Weichselbaum RR, Rowley DA, Kranz DM, Schreiber H.

J Exp Med. 2007 Jan 22;204(1):49-55. Epub 2007 Jan 8.

23.

A mutant chaperone converts a wild-type protein into a tumor-specific antigen.

Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC, Schreiber H.

Science. 2006 Oct 13;314(5797):304-8.

24.

Priming of naive T cells inside tumors leads to eradication of established tumors.

Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, Schietinger A, Philip M, Schreiber H, Fu YX.

Nat Immunol. 2004 Feb;5(2):141-9. Epub 2004 Jan 4.

Supplemental Content

Loading ...
Support Center